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INTRODUCTION
Octreotide (Sandostatin® Novartis, Berne, Switzerland) is a somatostatin analog approved for the treatment of acromegaly and gastrointestinal syndromes of hormone hypersecretion in Switzerland. Since somatostatin receptors (SSTR) are present on most meningiomas, octreotide has been suggested as a salvage treatment for patients with recurrent meningioma with presence of somatostatin receptors confirmed by octreotide SPECT or PET studies (1, 2) . We report the case of a patient with metastatic somatostatin receptor-positive meningioma who developed multifocal CNS demyelination after octreotide therapy.
CASE REPORT
The female polyallergic (latex, non-steroidal anti-inflammatory drugs, hayfever, contrast agent) patient was diagnosed with a left sphenoidal meningioma in 1995 at the age of 37. After partial resection the tumor was classified as a WHO grade I meningotheliomatous meningioma and subsequently partially resected again 3 and 7 years later due to progressive growth and subjected to postoperative radiotherapy with 50Gy in June 1999. At the age of 52, a thoracic CT scan carried out for prolonged coughing showed multiple bilateral pulmonary nodules. Histological examination Since the discontinuation of octreotide the patient has not reported additional neurological symptoms, but paraesthesia still appear after exposure to heat, e.g. in the sauna. Over the last 2 years, without treatment, the primary cerebral meningioma showed gradual progression, while an additional pulmonary metastase was detected on repeated scans. However, data indicate that somatostatin increases the susceptibility to develop experimental allergic encephalitis (EAE)(5) .
The octreotide doses administered to the patient (0,1mg 3x daily) differed from the dose and schedule originally described as salgave therapy for SSTR positive meningioma (30mg every 28days) (1, 2) . It is unclear in how far this might have increased the risk for this putative auto-immune mediated reaction.
Conclusion
This case indicates a possible risk for autoimmune mediated focal demyelination by octreotide treatment in polyallergic patients.
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